Hodgkin Lymphoma 
Welcome,         Profile    Billing    Logout  

173 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hodgkin Lymphoma
NCT03015896: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Active, not recruiting
1/2
36
US
Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
David Bond, MD, Bristol-Myers Squibb
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
12/24
12/24
BTCRC-HEM15-027, NCT03681561: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
1/2
54
US
Ruxolitinib, Jakafi, Nivolumab, Opdivo
Veronika Bachanova, Incyte Corporation, Bristol-Myers Squibb
Hodgkin Lymphoma
08/24
12/26
NCT03983668: CMP-001 for Relapsed and Refractory Lymphoma

Suspended
1/2
39
US
CMP-001, CYT003; QbG10; IND # 18627, Pembrolizumab, Keytruda
Umar Farooq, Checkmate Pharmaceuticals, Merck Sharp & Dohme LLC, University of Iowa
Lymphoma
04/25
04/26
NCT05565417: Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Recruiting
1/2
151
US
IMT-009, Fruquintinib, fruzaqla
Immunitas Therapeutics
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
04/25
04/25
NCT05103345: Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Recruiting
1/2
70
RoW
SGN1, SalMet-Vec
Guangzhou Sinogen Pharmaceutical Co., Ltd, Parexel
Advanced Solid Tumor
12/27
06/28
KEYNOTE-051, NCT02332668 / 2014-002950-38: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/)

Checkmark Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Dec 2019 - Dec 2019: Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Recruiting
1/2
370
Europe, US, RoW
Pembrolizumab, MK-3475
Merck Sharp & Dohme LLC
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
10/27
10/27
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
140
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
05/25
12/28
D9571C00001, NCT05216835 / 2021-003569-36: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, not recruiting
1/2
45
Europe, Canada, US
AZD7789
AstraZeneca, Parexel
Relapsed or Refractory Classical Hodgkin Lymphoma
02/26
10/27
NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Recruiting
1/2
81
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
NCT05955105: A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Recruiting
1/2
200
RoW
ILB-2109, Toripalimab
Innolake Biopharm
Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma
01/26
07/26
MK-4280-003, NCT03598608 / 2018-001461-16: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Checkmark Presentation of data from Phase 1/2 trial in R/R Classical Hodgkin Lymphoma at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from Phase 1/2 trial in R/R Classical Hodgkin Lymphoma at ASH 2022
Recruiting
1/2
174
Europe, Canada, US, RoW
pembrolizumab, KEYTRUDA®, MK-3475, Favezelimab, MK-4280
Merck Sharp & Dohme LLC
Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
04/28
04/28
NCT06018129: A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Recruiting
1/2
240
US, RoW
GEN3017, DuoBody® CD3xCD30
Genmab
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma
12/29
12/32
RELATIVITY-069, NCT05255601 / 2021-000493-29: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Recruiting
1/2
68
Europe, US, RoW
Relatlimab, BMS-986016, Nivolumab, BMS-936558
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Lymphoma, Non-Hodgkin, Hodgkin Disease
07/28
07/28
CTR20211029: A Phase Ia/Ib Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of SG12473 for Injection in Patients With Advanced Malignancies

Ongoing
1a/1b
165
China
SG12473 - Sumgen Biotech
Hangzhou Shangjian Biotechnology Co., Ltd./ Kaihui Wisdom Biotechnology (Shanghai) Co., Ltd
Advanced malignancy
 
 
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
NCT03061188: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Completed
1
15
US
Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pharmacological Study, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
Northwestern University, Bristol-Myers Squibb, AbbVie, National Cancer Institute (NCI)
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm
03/18
08/20
NCT06082596: Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Completed
1
32
RoW
BEBT-908 for injection, CUDC-908
BeBetter Med Inc
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
03/19
03/19
NCT00697684: Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Completed
1
29
US
Antithymocyte Globulin, Clofarabine
Beth Israel Deaconess Medical Center, Genzyme, a Sanofi Company
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Non Hodgkin's Lymphoma, Hodgkins Disease, Relapsed Refractory Multiple Myeloma
12/20
11/23
NCT03657381: Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520

Recruiting
1
75
RoW
Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Shandong New Time Pharmaceutical Co., LTD
Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
02/21
10/22
NCT03921879: Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Recruiting
1
50
US
OT-82 Dose Escalation, OT-82 Dose Expansion
Oncotartis, Inc.
Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
04/21
06/21
NCT03524235: Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Active, not recruiting
1
30
US
Total Body Irradiation, TBI, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Bendeka; Treanda, Fludarabine, Fludara, Rituximab, Rituxan
Noah Merin, Miltenyi Biomedicine GmbH, Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
11/21
11/31
NCT03212404: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Recruiting
1
500
Europe, RoW
CK-301 (cosibelimab)
Checkpoint Therapeutics, Inc., Novotech (Australia) Pty Limited
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Classical Hodgkin Lymphoma, Cutaneous Squamous Cell Carcinoma, Non Hodgkin Lymphoma, Endometrial Cancer
11/21
12/24
NCT03374007: Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

Recruiting
1
72
RoW
Geptanolimab Injection 1mg/kg, Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection, Geptanolimab Injection 3mg/kg, Geptanolimab Injection 10mg/kg, Geptanolimab Injection 1mg/kg, q2w*6, Geptanolimab Injection 3mg/kg, q2w*6, Geptanolimab Injection 10mg/kg, , q2w*6, Geptanolimab Injection 280mg, q3w, Geptanolimab Injection 3mg/kg, q2w
Genor Biopharma Co., Ltd.
Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma, Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
06/22
08/22
NCT03207958: Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Completed
1
10
US
Belimumab, Benlysta
Washington University School of Medicine, GlaxoSmithKline, American Cancer Society, Inc.
Graft Vs Host Disease, Graft-versus-host-disease
06/22
02/24
NCT04250324: Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Recruiting
1
21
RoW
BZ019
Shanghai Cell Therapy Group Co.,Ltd, Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital
Large B-cell Lymphoma
08/22
12/22
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
09/22
12/24
NEON-2, NCT04920383: ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Terminated
1
29
US
ALPN-202, pembrolizumab KEYTRUDA®
Alpine Immune Sciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Lymphoma
11/22
02/23
NCT02663518: A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Checkmark Additional data from trial for r/r hematologic malignancies at ASH 2021
Nov 2021 - Nov 2021: Additional data from trial for r/r hematologic malignancies at ASH 2021
Checkmark Updated data from P1a/b trial for CTCL, peripheral T-cell lymphoma and DLBCL
May 2021 - May 2021: Updated data from P1a/b trial for CTCL, peripheral T-cell lymphoma and DLBCL
Checkmark Data from trial for hematological malignancies
More
Terminated
1
249
Canada, US
PF-0791800 (TTI-621), TTI-621 (SIRPα-IgG1 Fc), PF-07901800 (TTI-621) plus Rituximab, TTI-621 plus Rituxan, PF-07901800 (TTI-621) plus Nivolumab, TTI-621 plus Opdivo
Pfizer
Hematologic Malignancies, Solid Tumor
11/22
11/22
SGNS40-001, NCT02376699: Safety Study of SEA-CD40 in Cancer Patients

Checkmark Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Jan 2022 - Jan 2022: Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Terminated
1
159
US
Intravenous (IV) SEA-CD40, SEA-CD40, Pembrolizumab, Keytruda, Subcutaneous (SC) SEA-CD40, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Seagen Inc., Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
03/23
04/23
NCT03894618: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Completed
1
49
Europe, Canada, US
SL-279252
Shattuck Labs, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
05/23
05/23
NCT04473911: Haplo Peripheral Blood Sct In GVHD Prevention

Active, not recruiting
1
25
US
FLUDARABINE, Fludara®, CYCLOPHOSPHAMIDE, Cytoxan®, Neosar®, TBI, Melphalan, Alkeran®, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Sirolimus, Rapamune, Mycophenolate mofetil, CellCept, Myfortic, RGI-2001
Zachariah Michael DeFilipp, Regimmune Corporation
GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
10/23
10/24
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Active, not recruiting
1
106
Europe, US
Tinostamustine
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
11/23
12/23
CS5001-101, NCT05279300: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1
156
US, RoW
CS5001
CStone Pharmaceuticals
Advanced Solid Tumor, Advanced Lymphoma
03/25
06/25
NCT04657965: LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Not yet recruiting
1
144
RoW
LMP1 CAR T-cells, LMP1 CAR-T cells injection
Zhejiang University, Yake Biotechnology Ltd.
Infectious Diseases, Hematological Malignancies
01/24
01/27
NCT04999384: First in Human, Dose Escalation Study of AN4005

Recruiting
1
31
US, RoW
AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect
Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumor, Advanced Lymphoma
08/24
12/24
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Active, not recruiting
1
55
US
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
06/24
09/24
TTI-622-01, NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Checkmark First patient dosed in combination with azacitidine for TP53-mutated AML
Aug 2021 - Aug 2021: First patient dosed in combination with azacitidine for TP53-mutated AML
Checkmark Data from trial for lymphoma
Apr 2021 - Apr 2021: Data from trial for lymphoma
Active, not recruiting
1
177
US
Maplirpacept (PF-07901801), SIRPα-IgG4 Fc, TTI-622, Azacitidine, VIDAZA, Venetoclax, VENCLEXTA, Carfilzomib, KYPROLIS, Dexamethasone, Anti-CD20 Targeting agent, Ruxience or Rituxan, Isatuximab, Sarclisa
Pfizer
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
09/24
09/24
SGN35C-001, NCT06254495: A Safety Study of SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
US
SGN-35C
Seagen Inc.
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
02/28
08/28
NCT06398457: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Not yet recruiting
1
8
NA
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score, JH-DSA Semi-Quant Screen Score, JH-DSA Semi-Quant Response Score
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Janssen Research & Development, LLC
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
06/26
12/26
NCT05567887: A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Active, not recruiting
1
7
Japan
maplirpacept (PF-07901801), TTI-622
Pfizer
Lymphoma, Multiple Myeloma
07/24
07/24
NCT04072458: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Recruiting
1
30
US
L-Bcl-2 antisense oligonucleotide, BP1002
Bio-Path Holdings, Inc.
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL
09/24
01/26
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26
NCT05293912: SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.

Recruiting
1
72
US
SG2501, Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody
Hangzhou Sumgen Biotech Co., Ltd.
Hematological Malignancy, Lymphoma
12/24
04/25
TORCH, NCT04187872: LITT and Pembrolizumab in Recurrent Brain Metastasis

Terminated
1
10
US
LITT + Pembrolizumab, NeuroBlate System, Keytruda
University of Florida, Monteris Medical
Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
12/23
12/23
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
NCT05225584: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Recruiting
1
120
US
KT-333
Kymera Therapeutics, Inc.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
02/25
03/25
CP-MGD024-01, NCT05362773: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
1
90
US
MGD024
MacroGenics
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
03/25
03/25
NCT05065866: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Active, not recruiting
1
14
US
BMS-986345, Oral Azacitidine, Duvelisib, Copiktra
H. Lee Moffitt Cancer Center and Research Institute, Secura Bio, Inc.
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
03/24
03/25
SURYA-1, NCT05605119: First in Human, Dose Escalation, Dose Expansion Study of AUR105

Recruiting
1
40
RoW
AUR105
Aurigene Discovery Technologies Limited
Solid Tumor, Adult, Non-hodgkin Lymphoma, Hodgkin Lymphoma
12/25
05/26
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting
1
49
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
09/26
12/26
NCT04231877: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Suspended
1
50
US
Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, 174722-31-7, 687451, ABP 798, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-C2B8 Monoclonal Antibody, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, rituximab-abbs, Rituximab Biosimilar SIBP-02, Riabni, Rituximab ARRX, Rituximab PVVR, Ruxience, Prednisone, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Metacortandracin, Meticorten, Ofisolona, Panafcort, Paracort, Predicor, Predicorten, Prednidib, Prednilonga, Prednitone, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Filgrastim-aafi, Nivestym
University of Washington, Genentech, Inc.
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
12/26
12/31
CLIO-1, NCT02651662 / 2015-001697-17: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Checkmark Data from monotherapy or in combination with REGN1979 at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: Data from monotherapy or in combination with REGN1979 at ASH 2017 [screenshot]
Recruiting
1
62
Europe, US
cemiplimab, REGN2810, Libtayo, odronextamab, REGN1979
Regeneron Pharmaceuticals
Relapsed/Refractory Aggressive B-Cell Lymphoma
12/26
12/26
NCT03696784: Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Recruiting
1
30
US
iC9-CAR19 T cells, Bendamustine, Treanda, Bendeka, Fludarabine, Fludara, AP1903, Rimiducid, Cyclophosphamide, Cytoxan, Neosar
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, The V Foundation
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
03/27
03/43
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, US
SGN-35T
Seagen Inc.
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
APOLLO, NCT05798897: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Recruiting
1
79
US
MT-601
Marker Therapeutics, Inc.
Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
02/28
02/28
jRCT1080224013: Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)

Completed
N/A
250
Japan
Opdivo (nivolumab) - BMS
Ono Pharmaceutical Co., Ltd.
Classical Hodgkin's lymphoma
 
 
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No Longer Available
N/A
US
Plerixafor, AMD3100, Mozobil
Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
 
 
NCT01196208 / 2010-020363-21: A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

No Longer Available
N/A
Europe, US, RoW
brentuximab vedotin, SGN-35
Seagen Inc., Millennium Pharmaceuticals, Inc.
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous
 
 
NCT03200977: Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

Active, not recruiting
N/A
95
US
Non-Interventional
Bristol-Myers Squibb
Lymphoma
06/22
12/22
MargheRITA, NCT05260203: (Remote Intelligence for Therapeutic Adherence)

Completed
N/A
124
Europe
RITA (App)
Advice Pharma Group srl
Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma, Lymphocytic Lymphoma, Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder, Treatment Adherence, Treatment Adherence and Compliance
01/23
01/23
NCT04776265: RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Recruiting
N/A
100
RoW
Evaluation of therapeutical approach after ASCT
Grupo Argentino de Tratamiento de la Leucemia Aguda, Takeda
Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
03/24
04/24
NCT04237233: Intense Monitoring Study on Tyvyt

Recruiting
N/A
300
RoW
Innovent Biologics (Suzhou) Co. Ltd.
Relapsed or Refractory Classical Hodgkin's Lymphoma
06/23
12/23
NCT04213209: Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Completed
N/A
95
Japan
Brentuximab Vedotin (Genetical Recombination), ADCETRIS Intravenous Infusion 50 mg
Takeda
Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma
12/23
12/23
NCT04665063: A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
20
RoW
Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital
Hodgkin's Lymphoma
10/23
10/25
NCT06363201: Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours

Not yet recruiting
N/A
40
RoW
Ocoxin Oral solution
Catalysis SL
Advanced Cancer, Advanced Solid Tumor, Lymphoma, Hodgkin, Central Nervous System Tumor, Sarcoma, Germ Cell Tumor, Pediatric Cancer
12/24
12/25
HAPLO2022, NCT06225050: M-2018-334 in Hematological Malignancies

Not yet recruiting
N/A
18
NA
CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
Miltenyi Biomedicine GmbH, City of Hope Comprehensive Cancer Center
Hematological Malignancies
04/27
04/27
BELIEVE, NCT04998331: A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

Active, not recruiting
N/A
51
Europe
No Intervention
Takeda
Hodgkin Disease, Lymphoma, T-Cell, Cutaneous
06/24
06/24
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn
N/A
200
RoW
No Intervention
Takeda
Hodgkin Lymphoma
10/24
10/24
NCT01868451: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active, not recruiting
N/A
118
US
Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
Memorial Sloan Kettering Cancer Center, Seagen Inc., University of Rochester, City of Hope Medical Center, Stanford University
Hodgkin Lymphoma
05/26
05/26
BV-MAZOVIA, NCT05100056: A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting
N/A
70
Europe
No Intervention
Takeda
Hodgkin Lymphoma
06/26
06/26
NCT05481437: A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Recruiting
N/A
8
Japan
Brentuximab Vedotin, ADCETRIS Intravenous Infusion
Takeda
Hodgkin Lymphoma
12/27
12/27
PASCA, NCT04671693: A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.

Recruiting
N/A
858
Europe
PASCA intervention
Centre Leon Berard, Malakoff-Humanis, Fondation Apicil, Fédération Leucémie Espoir, Biogaran, Le défi Anthony, Novartis, Roche Pharma AG
Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma
01/28
04/28
LYM0001, NCT00398177: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

Recruiting
N/A
9999
US
Stanford University, The Leukemia and Lymphoma Society, Biospect Inc
Lymphoma, Non-Hodgkin, Hodgkin's Disease
01/99
01/99
 

Download Options